1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Genentech’s PFS Data May Help Inavolisib Compete In PI3KCA-Mutated Breast Cancer

 
• By Joseph Haas

Inavolisib meets statistical significance for progression-free survival in HR+/HER2- advanced breast cancer with a PI3KCα mutation, which could set up competition with Piqray, Ibrance and Kisqali.

Genetech
Genentech's inavolisib may offer a new treatment option in HR+/HER2- breast cancer • Source: Shutterstock: Michael Vi

Genentech, Inc. may have taken a strategically important step in the treatment of HR+/HER2- advanced breast cancer with a PI3KCA mutation on 5 December with pivotal data showing that its inavolisib can provide statistically significant progression-free survival (PFS) versus a comparator regimen.

Key Takeaways

  • Genentech’s inavolisib demonstrates a progression-free survival benefit in HR+/HER2-negative breast cancer.

While the Roche Holding AG division did not share numerical data from the Phase III INAVO120 study, Genentech announced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Prilenia, Ferrer Map Out Plans For Pridopidine In Huntington’s

 
• By Alaric DeArment

The companies announced the publication of Phase III data that they said provide rationale for moving forward in a confirmatory trial.

AC Immune Cuts Workforce As Key Parkinson’s Readout Nears

 
• By Andrew McConaghie

The Swiss neuroscience specialist has extended its cash runway into late 2027, but will still need positive readouts in the coming months, including for its wholly owned Parkinson’s candidate.

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

 
• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

 
• By Jessica Merrill

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.

More from R&D

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.